Efficacy Insights & Helping CLD Patients | DOPTELET® (avatrombopag) HCP

ADAPT‐1 and ADAPT‐2 were 2 identically designed, multicenter, randomized, double‐blind, placebo‐controlled studies (N=435)^1,2

Primary endpoint: Proportion of patients who did not require a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following an elective procedure.¹

Secondary endpoint: Proportion of patients who achieved platelet counts of >50x10⁹/L on the day of procedure, and the change in platelet count from baseline to procedure day.¹

Biliary interventions
Bronchoscopy +/- biopsy
Chemoembolization for HCC
Colonoscopy +/- polypectomy/biopsy
Dental procedures
Ethanol ablation

Laparoscopic interventions
Liver biopsy
Nephrostomy tube placement
Paracentesis
Radiofrequency ablation
Renal biopsy

Thoracentesis
Transjugular intrahepatic portosystemic shunt
Upper GI endoscopy +/- biopsy
Upper GI endoscopy +/- sclerotherapy
Upper GI endoscopy +/- variceal banding
Vascular catheterization

In the ADAPT studies, the percentage of patients who underwent procedures with low, moderate, or high risk was as follows: low 60.8%; moderate 17.2%; and high 22.1%.²

Primary endpoint: Patients not requiring a platelet transfusion or any rescue procedure for bleeding up to 7 days following a scheduled procedure.¹

88%

of high-baseline patients taking Doptelet
achieved the primary endpoint (N=117).¹

66%

of low-baseline patients taking Doptelet
achieved the primary endpoint (N=90).¹

Mean platelet counts nearly doubled with Doptelet¹

With Doptelet, platelet counts significantly increased by procedure day.¹

UP TO

45,000

in high-baseline patients

AND

+32,000

in low-baseline patients¹

97% of patients whose platelet counts were measured on procedure day had an increase with Doptelet.^1,3†

IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

93%

of high-baseline patients reached the
50,000 platelets/μL target (N=58).¹

69%

of low-baseline patients reached the
50,000 platelets/μL target (N=90).¹

Explore the safety profile of Doptelet

Learn more about the pooled safety data from ADAPT-1 and ADAPT-2 studies.

VIEW SAFETY

^{PC=platelet count; R=randomized; qd=every day.}

*From randomization of Doptelet 40 mg or Doptelet 60 mg once daily for 5 days up to 7 days after a procedure compared to placebo (P<0.0001; N=435).¹

^†270/277 patients treated with Doptelet in ADAPT-1 and ADAPT-2 had increased platelet counts by procedure day.^1,3

DOPTELET (avatrombopag) [prescribing information]. Durham, NC: AkaRx, Inc; 2021.
Terrault N, Chen Y, Izumi N, et al. Avatrombopag before procedures reduces needs for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):718.
Data on file. The SAS System. 2023: Sobi, Inc.

Discover the Doptelet Copay Program

Eligible commercially insured patients may qualify for the Doptelet Connect program

What's the program?

Eligible patients may pay as little as $0 for each Doptelet prescription

Annual maximum benefit up to $15,000

Eligible patients must:

Have commercial insurance that covers Doptelet

Not be enrolled in any state or federal healthcare program such as Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD), or TRICARE

Be 18 years of age or older

Be a resident in the United States or a US Territory

How to enroll:

Approved pharmacies, healthcare professionals, and Doptelet Connect can enroll patients

Patients can enroll themselves as well as their caregivers

Please call 1-833-368-2663 Monday–Friday 8am–8pm ET for more information

Terms and Conditions

Patients pay as little as $0 per prescription. Copay Program has an annual calendar cap of $15,000

The Copay Saving Program is void where prohibited by law, taxes, or restricted

This offer is non-transferable, no substitutions are permissible, and this offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription

Sobi, Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice

The Patient Copay Program for Doptelet is not insurance and is not intended to substitute for insurance

Patients, pharmacists, and healthcare providers must not seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this Copay Program. Patients must not seek reimbursement from any health savings, flexible spending, or other healthcare reimbursement accounts for the amount of assistance received from the Copay Program

Certain information pertaining to your use of the Copay Program will be shared with Sobi, Inc., the sponsor of the Copay Program. The information disclosed will include the date the prescription is filled, the number of pills or product dispensed by the pharmacists, and the amount of your copay that will be paid for by using this Copay Program. For more information, please see the Sobi Privacy Policy at https://sobi-northamerica.com/privacy-policy

Acceptance in this Program is not conditioned on any past, present, or future purchase, including additional doses

Enrollment for the Copay Program is valid through the calendar year

Sobi reserves the right to change program terms at any time

CONSISTENT EFFICACY

In 2 pivotal studies that included procedures ranging from low to high bleeding risk.¹

ADAPT‐1 and ADAPT‐2 were 2 identically designed, multicenter, randomized, double‐blind, placebo‐controlled studies (N=435)^1,2

Doptelet^® (avatrombopag) helps protect patients during and after a scheduled procedure¹

88%

66%

Mean platelet counts nearly doubled with Doptelet¹

UP TO

45,000

AND

+32,000

With Doptelet, patients can be ready for procedure day with ≥50,000 platelets/μL¹

93%

69%

Explore the safety profile of Doptelet

CONSISTENT EFFICACY

In 2 pivotal studies that included procedures ranging from low to high bleeding risk.1

ADAPT‐1 and ADAPT‐2 were 2 identically designed, multicenter, randomized, double‐blind, placebo‐controlled studies (N=435)1,2

Eligible Procedures in the ADAPT-1 and ADAPT-2 Studies2

Doptelet® (avatrombopag) helps protect patients during and after a scheduled procedure1Doptelet significantly reduced the need for platelet transfusions or rescue procedures for bleeding for up to 7 days post procedure.1*

Doptelet® (avatrombopag) helps protect patients during and after a scheduled procedure1

88%

66%

Mean platelet counts nearly doubled with Doptelet1

UP TO

45,000

AND

+32,000

With Doptelet, patients can be ready for procedure day with ≥50,000 platelets/μL1Significantly more patients achieved a platelet count of ≥50,000/μL with Doptelet.1

With Doptelet, patients can be ready for procedure day with ≥50,000 platelets/μL1

93%

69%

Explore the safety profile of Doptelet

Footnotes

References

Discover the Doptelet Copay Program

Eligible commercially insured patients may qualify for the Doptelet Connect program

What's the program?

Eligible patients must:

How to enroll:

Terms and Conditions

In 2 pivotal studies that included procedures ranging from low to high bleeding risk.¹

ADAPT‐1 and ADAPT‐2 were 2 identically designed, multicenter, randomized, double‐blind, placebo‐controlled studies (N=435)^1,2

Doptelet^® (avatrombopag) helps protect patients during and after a scheduled procedure¹

Mean platelet counts nearly doubled with Doptelet¹

With Doptelet, patients can be ready for procedure day with ≥50,000 platelets/μL¹